We sought to define prognostic factors for survival in Waldenstrom macroglobulinaemia (WM). Of 585 patients diagnosed with WM and seen at Mayo Clinic between 1960 and 2001, 337 symptomatic patients met the inclusion criteria and were analysed for overall and disease-specific survival. The median survival from the time of diagnosis was 6·4 years. The median disease-specific survival was 11·2 years. Univariate analysis for overall survival identified the following adverse prognostic factors: age >65 years (P < 0·001), organomegaly (P < 0·001), elevated β2-microglobulin (<0·001), anaemia (Hb < 10·0 g/dl) (P = 0·01), leucopenia (<4·0 × 10 9/l) (P = 0·03), thrombocytopenia (<150 × 10 9/l) (P = 0·01), serum albumin <40 g/l (P = 0·001), and quantitative IgM < 0·4 g/l (P = 0·04). On multivariate analysis, age >65 years and organomegaly were associated with poor prognosis. A prognostic model was built based on these two variables. Patients at high risk (1-2 risk factors, median survival 4·2 years) experienced worse survival than patients at low risk (0 risk factors, median survival 10·6 years), P < 0·001. The prognostic model was validated in 204 patients who were not included in the analysis cohort. β2-microglobulin ≥4 mg/l was associated with a threefold increase in the risk of death when added to the prognostic model. We describe a simple prognostic model for overall survival for newly diagnosed patients with WM.
- Beta 2-microglobulin
- Prognostic factors
- Prognostic model
- Waldenstrom macroglobulinaemia
ASJC Scopus subject areas